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Abstract
Chronic respiratory infection caused by Pseudomonas aeruginosa is the main driver of morbidity and mortality in cystic ﬁbrosis (CF)
patients. The development of resistance to all available antibiotics is a frequent outcome of these infections. The present study aimed
to evaluate the activity of the new cephalosporin CXA-101 (FR264205) against a collection of 100 isolates obtained from 50 CF patients
from two Spanish hospitals. The collection included the ﬁrst (early) and the last (late) available isolate from each patient (average inter-
val 68 ± 39 months). The MIC50 and MIC90 of CXA-101 were 0.5 and 2 mg/L and the geometric mean MIC was 0.7 mg/L; the MICs for
95% of the isolates were £8 mg/L (tentative breakpoint). Only meropenem yielded comparable results, although the MIC90 of this anti-
biotic was signiﬁcantly higher (8 mg/L). CXA-101 showed conserved activity against a high proportion of isolates resistant to each of
the antibiotics tested (ceftazidime, cefepime, piperacillin-tazobactam, imipenem, meropenem, levoﬂoxacin and tobramycin), with MIC50
values of 1–2 mg/L. Moreover, CXA-101 retained good activity against multidrug-resistant strains, with MIC50 and MIC90 values of 2
and 16 mg/L. CXA-101 was also active against late CF isolates (the MIC for 96% was £8 mg/L); it was the only antibiotic tested to
which a similar percentage of early and late isolates was susceptible. These results show that, despite a slight increase in MICs, major
cross-resistance to CXA-101 did not develop during treatment of CF patients with the currently available antipseudomonal agents.
Therefore, CXA-101 is envisaged as a valuable alternative for the treatment of chronic respiratory infection caused by P. aeruginosa in
CF patients.
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Introduction
Chronic respiratory infection (CRI) due to Pseudomonas aeru-
ginosa is the main cause of morbidity and mortality in cystic
ﬁbrosis (CF) patients [1,2]. One of the most concerning fea-
tures of these infections is the extraordinary capacity of
P. aeruginosa to develop resistance to almost all available
antibiotics through the selection of mutations in
chromosomal genes [3], facilitated by the very high preva-
lence of hypermutable (or mutator) strains deﬁcient in the
DNA mismatch repair system [4,5]. Indeed, sequential devel-
opment of multidrug-resistance (MDR) is a frequent out-
come [6] that has a major impact on disease progression [7].
Among the mutation-mediated resistance mechanisms, par-
ticularly noteworthy are those leading to the repression or
inactivation of the porin OprD, conferring resistance to car-
bapenems [8], or those leading to the hyperproduction of
the chromosomal cephalosporinase AmpC, such as the inac-
tivation of AmpD or PBP4 [9,10], thereby determining resis-
tance to currently available penicillins and cephalosporins.
Also remarkable is that mutations leading to the up-regula-
tion of one of the several efﬂux pumps encoded in the
P. aeruginosa genome may confer resistance or reduced sus-
ceptibility to multiple agents, including most b-lactams, ﬂuor-
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oquinolones and aminoglycosides [11,12]. Moreover, multiple
antibiotic-resistant variants frequently coexist in the lungs of
chronically-infected CF patients [13]. In addition to antibiotic
resistance mutations, several other adaptive mutations pro-
mote the long-term persistence of CRI, making its eradica-
tion with conventional antimicrobial therapy extremely
difﬁcult, if not impossible [14,15]. Among those worthy of
note are mutations causing the inactivation of mucA that
leads to alginate hyperproduction [16]. Mucoid variants are
found in 80–90% of chronically-infected patients and are
associated with a poorer pulmonary outcome [17]. Alginate
hyperproduction is known to reduce bacterial clearance and
to inhibit phagocytosis, complement activation, antibiotic
penetration and neutralization of oxygen radicals [18–21].
Other important adaptive variants frequently found among
P. aeruginosa isolates from CRI (up to 50% of CF patients
colonized by P. aeruginosa) are the small colony variants
(SCV) [22]. These mutants, which are characterized by their
reduced colony size (1–3 mm) in agar-based culture media,
have been associated with increased antimicrobial resistance,
notably to aminoglycosides, and poorer lung function in CF
patients [22].
Over the last two decades, there has been very limited
progress in developing antipseudomonal antibiotics that can
overcome MDR in P. aeruginosa. CXA-101 (former
FR254205) is a new cephalosporin antibiotic in phase 2 clini-
cal development by Calixa Therapeutics Inc. (San Diego,
CA, USA) that shows promising characteristics for the
treatment of P. aeruginosa infections because it appears to
be stable against the most common mechanisms of resis-
tance acquired through mutation in this species [23,24]. In
the present study, we evaluated the activity of CXA-101
and antipseudomonal comparators against a collection of
P. aeruginosa sequential (early and late) isolates, including
mucoid and SCV variants, from chronically-infected CF
patients in Spain.
Materials and Methods
Strains
A collection of 100 P. aeruginosa isolates obtained from 50
CF patients treated at two different Spanish hospitals (Hospi-
tal Universitario Ramo´n y Cajal in Madrid and Hospital Son
Dureta in Palma de Mallorca) was tested. The collection
included the ﬁrst and the last available P. aeruginosa isolates
from each of the 50 chronically-infected CF patients. The
intervals between the ﬁrst (early) and last (late) isolates ran-
ged from 2 to 164 months (average 67.6 ± 39.2 months).
The collection included patients with incipient P. aeruginosa
infection as well as patients with long-term (over 13 years)
chronic infection. The isolates were further classiﬁed,
according to the major CF morphotypes, in mucoid strains
[16], SCV [22] and others (non-mucoid non-SCV isolates).
All patients had received frequent antipseudomonal treat-
ments, including maintenance aerosol therapy (mainly tobra-
mycin) and several intravenous courses with different
combinations of b-lactams, aminoglycosides, and ﬂuoroquin-
oles during acute exacerbations.
Susceptibility testing
The MICs of CXA-101, ceftazidime (CAZ), cefepime (FEP),
piperacillin-tazobactam (PTZ), imipenem (IMP), meropenem
(MER), tobramycin (TOB), and levoﬂoxacin (LEV) were
determined by standard CLSI broth microdilution (M100-
S18) [19]. CXA-101 (Lot 3F02) was provided by Calixa
Therapeutics Inc (San Diego, CA, USA). Other antibiotics
were purchased from commercial sources. The range of con-
centrations tested was from 0.12 mg/L to 64 mg/L. The sus-
ceptibility breakpoints deﬁned by the CLSI [25] were used
for all comparator antibiotics. When speciﬁcally indicated,
susceptibility data were also analysed applying EUCAST
(http://www.eucast.org) breakpoints. The tentative break-
point considered for CXA-101 was £8 mg/L for the suscepti-
ble category, which is the CLSI and EUCAST susceptibility
breakpoint used for the other antipseudomonal cephalospo-
rins CAZ and FEP. This tentative breakpoint is further sup-
ported by recent pharmacokinetics/pharmacodynamics (PK/
PD) studies [26]. P. aeruginosa reference strains PAO1 and
ATCC 27853 were tested in parallel for quality control.
MDR strains were deﬁned as those nonsusceptible (interme-
diate or resistant) to at least three of the following four anti-
biotics: CAZ, IMP, LEV and TOB.
Results
The distribution of MICs of CXA-101 and comparators for
the collection of CF isolates is shown in Table 1. Table 2
contains data on MIC50, MIC90, geometric mean of MICs,
and the percentage of isolates susceptible and resistant to
each of the antibiotics tested.
When the complete collection of CF isolates was consid-
ered, the MIC50 and MIC90 of CXA-101 were 0.5 and 2 mg/
L, respectivey, and the geometric mean MIC was 0.7 mg/L.
These values were only comparable to those obtained for
MER, although the MIC90 of this antibiotic was signiﬁcantly
higher (8 mg/L). The MIC50, MIC90 and mean MICs of all the
other antibiotics tested were signiﬁcantly higher (Table 2). In
terms of susceptibility percentages, using the 8 mg/L break-
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point, CXA-101 was the most active antibiotic (95% of iso-
lates susceptible) followed by PTZ (87%) and MER (86%),
whereas the activities of IMP (52%), CAZ (75%), FEP (63%),
LEV (67%) or TOB (77%) were signiﬁcantly lower. Suscepti-
bility percentages for CAZ, FEP, IMP or TOB would not be
modiﬁed by the application of the EUCAST (instead of the
CLSI) breakpoints because both agencies use the same sus-
ceptibility breakpoints for these antibiotics. However, the
application of EUCAST susceptibility breakpoints for PTZ
(S £ 16 mg/L), MER (S £ 2 mg/L) and LEV (S £ 1 mg/L)
would signiﬁcantly reduce the percentages of susceptibility to
these antibiotics: 79% for PTZ, 70% for MER and 47% for
LEV (data not shown).
When the susceptibility of early vs. late colonizing isolates
was analysed, as expected, a clear trend for MICs to increase
over time (higher MIC50, MIC90 and mean MIC) was
detected for all the antibiotics tested, including CXA-101.
Nevertheless, as for the complete collection, the activity of
CXA-101 against late isolates was comparable to that of
MER, and signiﬁcantly more potent than those of all the
other antibiotics tested (Table 2). In terms of susceptibility
percentages, CXA-101 (96%) was the most active antibiotic
against the late CF isolates, followed, by a margin, by PTZ
(84%) and MER (82%). The susceptibility to CAZ (70%), FEP
(60%), LEV (60%) or IMP (42%) was particularly low against
late CF isolates (Table 2).
The activity of CXA-101 against isolates nonsusceptible
(intermediate or resistant) to the other antibiotics tested is
shown in Table 3. CXA-101 was active against the majority of
isolates nonsusceptible to each of the other antibiotic tested,
with MIC50 values of 1–2 mg/L. In terms of susceptibility per-
centages, considering the £8 mg/L breakpoint, CXA-101
showed very good activity against isolates nonsusceptible to
IMP (92% susceptible), LEV (91%), FEP (87%), CAZ (84%) and
MER (79%). The activity was slightly lower against PTZ nonsus-
ceptible isolates, although nine of the 13 (69%) PTZ resistant
isolates were susceptible to CXA-101 (Table 3)
By contrast, all isolates (n = 5) showing CXA-101 MICs ‡
8 mg/L were CAZ- and FEP-resistant, and four of the ﬁve were
also PTZ- and IMP-resistant. Finally, CXA-101 retained good
activity against MDR strains, with MIC50 and MIC90 values of 2
and 16 mg/L and MICs £ 8 mg/L for 84% of the isolates.
TABLE 1. Distribution of MICs of CXA-101 and comparators for a collection of 100 P. aeruginosa isolates obtained from 50
chronically-colonized cystic ﬁbrosis patients
Antibiotic (breakpoints)a
Number of isolates (%) inhibited at each antibiotic concentration (mg/L)
(MIC50 and MIC90 are respectively highlighted in light and dark grey)
£ 0.12 0.25 0.5 1 2 4 8 16 32 64 ‡ 128
CXA-101 9 20 32 19 11 1 3 1 2 1 1
CAZ (S £ 8-R ‡ 32) 1 1 2 5 25 23 18 6 6 4 9
FEP (S £ 8-R ‡ 32) 1 1 0 5 12 19 25 14 15 5 3
PTZ (S £ 64-R ‡ 128) 0 0 23 9 8 21 6 12 5 3 13
IMP (S £ 4-R ‡ 16) 2 0 6 6 11 26 20 14 2 5 7
MER (S £ 4-R ‡ 16) 25 14 15 16 11 5 7 3 2 2 0
TOB (S £ 4-R ‡ 16) 13 19 22 10 4 9 6 9 1 3 4
LEV (S £ 2-R ‡ 8) 1 8 15 23 20 11 13 6 2 1 0
aThe CLSI susceptibility and resistance breakpoints (mg/L) are indicated. The tentative susceptibility breakpoint considered for CXA-101 is 8 mg/L.
CAZ, ceftazidime; FEP, cefepime; PTZ, piperacillin-tazobactam; IMP, imipenem; MER, meropenem; TOB, tobramycin; LEV, levoﬂoxacin.
TABLE 2. Susceptibility data for CXA-101 and comparators in a collection of 100 Pseudomonas aeruginosa isolates, including
the ﬁrst (early) and the last (late) available isolates obtained from 50 cystic ﬁbrosis patients
Antibiotic (breakpoints)a
Susceptibility data for the overall collection/early isolates/late isolates
MIC50 (mg/L) MIC90 (mg/L) Mean MIC (mg/L) % Susceptible % Intermediate % Resistant
CXA-101 0.5/0.5/1 2/2/4 0.7/0.6/0.9 95/94/96 – –
CAZ (S £ 8-R ‡ 32) 4/4/8 64/64/128 5.9/4.7/7.5 75/80/70 6/6/6 19/14/24
FEP (S £ 8-R ‡ 32) 8/8/8 32/32/64 8.1/7.2/9.2 63/66/60 14/14/14 23/20/26
PTZ (S £ 64-R ‡ 128) 4/4/4 128/128/128 4.8/4.6/5.1 87/90/84 – 13/10/16
IMP (S £ 4-R ‡ 16) 4/4/8 64/32/128 6.0/4.7/7.7 52/62/42 20/18/22 28/20/36
MER (S £ 4-R ‡ 16) 0.5/0.5/0.5 8/8/16 0.74/0.61/0.88 86/90/82 7/6/8 7/4/10
TOB (S £ 4-R ‡ 16) 0.5/0.5/1 16/8/64 1.2/0.9/1.7 77/84/70 6/8/4 17/8/26
LEV (S £ 2-R ‡ 8) 2/1/2 16/8/16 1.8/1.5/2.2 67/74/60 11/8/14 22/18/26
aThe CLSI susceptibility and resistance breakpoints (mg/L) are indicated and applied. The tentative susceptibility breakpoint considered for CXA-101 is 8 mg/L.
CAZ, ceftazidime; FEP, cefepime; PTZ, piperacillin-tazobactam; IMP, imipenem; MER, meropenem; TOB, tobramycin; LEV, levoﬂoxacin.
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Of the 100 CF isolates tested, 51 were found to have the
mucoid phenotype, whereas 19 were SCV. The activity of
CXA-101 and comparators against these major CF morpho-
types is shown in Table 4. Both the SCV and mucoid isolates
showed signiﬁcantly lower susceptibility percentages, with
increased MICs (two- to ten-fold higher mean MICs) of all
antibiotics tested compared to other morphotypes (non-
mucoid non-SCV isolates). Additionally, SCV were much less
frequently susceptible to TOB than mucoid strains (47% vs.
82%), whereas the susceptibility to all other antibiotics was
similarly reduced in both morphotypes. Again, CXA-101 and
MER were the most potent antibiotics against SCV and
mucoid strains, with a mean MIC of approximately 1 mg/L.
Moreover, the percentages of susceptibility to CXA-101
were highest, both in the case of SCV (89%) and mucoid
strains (94%).
Discussion
Although P. aeruginosa eradication from the respiratory tract
of CF patients, by early aggressive antimicrobial therapy,
might still be possible during initial colonization [27], once
CRI is fully established, this goal is generally no longer attain-
able. In any case, effective antibiotic treatments are still
greatly needed for CRI to maintain the basal bacterial densi-
ties as low as possible and to restore the basal densities as
quickly as possible after the frequent acute exacerbations
[28] .
Antimicrobial therapy of CRI generally includes the use of
maintenance tobramycin or colistin inhalation treatments, as
well as repeated intravenous courses of b-lactams or ﬂuoro-
quinoles combined with aminoglycosides for acute exacerba-
tions [28]. Unfortunately, after years of CRI, sequential
development of resistance to all the available antibiotics is a
frequent outcome. Indeed, antimicrobial resistance rates
among CF isolates are signiﬁcantly higher than those docu-
mented in any other type of infection, including those occur-
ring in the intensive care unit setting [4,29]. Moreover, MDR
development is a frequent event [6] and has been demon-
strated to have a major impact on the progression of the
disease [7].
Over the last two decades, very limited progress has been
made in developing anti-pseudomonal agents that can over-
come MDR in P. aeruginosa. Among the recently introduced
antibiotics, only doripenem appears to have slightly enhanced
activity against MDR CF isolates [30]. Nevertheless, cross-
resistance between doripenem and available carbapenems,
particularly MER, has been documented [31], potentially lim-
iting the impact of this antimicrobial agent.
TABLE 4. Susceptibility data for CXA-101 and comparators in a collection of 100 cystic ﬁbrosis Pseudomonas aeruginosa iso-
lates, according to morphotype
Morphotype
(number of isolates)
% Susceptible/geometric mean MIC (mg/L)a
CXA-101 CAZ (S £ 8) FEP (S £ 8) PTZ (S £ 64) IMP (S £ 4) MER (S £ 4) LEV (S £ 2) TOB (S £ 4)
SCV (n = 19) 89/1.1 63/8.0 42/14.3 84/4.6 42/8.0 84/0.8 42/3.6 47/5.4
Mucoid (n = 51) 94/0.8 67/7.7 59/9.9 84/6.8 45/7.6 82/1.1 63/2.1 82/1.1
Othersb (n = 30) 100/0.4 97/3.2 83/4.0 93/2.8 70/3.3 93/0.4 90/1.0 87/0.6
aThe CLSI susceptibility breakpoints are indicated and applied. The tentative susceptibility breakpoint considered for CXA-101 is 8 mg/L.
bNon-mucoid, non-small colony variant (SCV).
CAZ, ceftazidime; FEP, cefepime; PTZ, piperacillin-tazobactam; IMP, imipenem; MER, meropenem; LEV, levoﬂoxacin; TOB, tobramycin.
TABLE 3. Activity of CXA-101
against isolates not susceptible to
the comparator antibiotics. Nonsusceptible
isolatesa
CXA-101 susceptibility data
MIC50 (mg/L) MIC90 (mg/L)
Geometric Mean
MIC (mg/L)
n (%) of isolates with
CXA-101 MIC £ 8 mg/L
IMP (n = 48) 1 8 1.0 44 (91.7)
FEP (n = 37) 1 16 1.7 32 (86.5)
LEV (n = 33) 1 8 1.3 30 (90.9)
CAZ (n = 25) 1 32 2.0 21 (84.0)
TOB (n = 23) 1 32 1.7 19 (82.6)
MER (n = 14) 2 32 2.3 11 (78.6)
PTZ (n = 13) 2 64 4.7 9 (69.2)
MDR (n = 19) 2 16 2.2 16 (84.2)
aThe CLSI intermediate and resistance categories are included.
bMDR strains were deﬁned as those not susceptible to at least three of the following four antibiotics: CAZ, IMP, LEV
and TOB.
IMP, imipenem; FEP, cefepime; LEV, levoﬂoxacin; CAZ, ceftazidime; TOB, tobramycin; MER, meropenem; PTZ, pipera-
cillin-tazobactam; MDR, multidrug-resistance.
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CXA-101, previously designated FR2654205, is a new
cephalosporin with promising characteristics for the treat-
ment of P. aeruginosa infections because it appears to be sta-
ble against the most common mechanisms of resistance
acquired through mutation in this species [23,24]. In initial
studies, Takeda et al. [24] tested 193 P. aeruginosa isolates
from Japan, documenting the excellent activity of FR264205
(MIC50/MIC90 = 0.5/1 mg/L), although the collection included
only a limited number of cephalosporin (CAZ)-resistant iso-
lates (13/193). These initial studies also showed conserved
activity against mutants overexpressing different P. aeruginosa
efﬂux pumps, as well as against simple AmpD mutants show-
ing moderately increased AmpC expression and b-lactam
resistance [23,24]. The high stability in the presence of
AmpC-mediated resistance was further conﬁrmed in a
recent study by our group [32] in which we evaluated the
activity of CXA-101 against a highly challenging collection of
strains with multiple combinations of mutations leading to
different degrees of AmpC overexpression (ampD, ampDh2,
ampDh3 and dacB (PBP4)) and porin loss (oprD). Indeed,
CXA-101 was found to be the only b-lactam tested (includ-
ing CAZ, FEP, PTZ, aztreonam, IMP and MER) conserving
high activity (MICs £ 2 mg/L) against strains containing com-
binations of all of these mutations [32].
We also recently evaluated a collection of non-CF carba-
penem-resistant and MDR P. aeruginosa isolates obtained
from a multicentre study in Spain [33]; CXA-101 showed
good activity against that collection of isolates (MIC50/MIC90
of 1/4 mg/L, 95% MICs £ 8mg/L) and, interestingly, almost all
of the CXA-101-nonsusceptible isolates produced an MBL or
ESBL encoded by a horizontally-acquired gene, consistent
with the previously observed stability against mutation-medi-
ated resistance mechanisms. Nevertheless, the available
information on the activity of CXA-101 against isolates from
CF patients is still limited. A single study by Livermore et al.
[34] recently evaluated a highly challenging panel of 56 MDR
P. aeruginosa isolates from CF patients and found that CXA-
101 was the most active drug. In the same study, the activity
of CXA-101 against isolates of Burkholderia cepacia, another
relevant (although much less frequent) CF pathogen, was
similar to that of CAZ [34]. Moreover, very recent data
show that the activity of CXA-101 against Enterobacteriaceae
and Gram-positive cocci might be similar to other extended-
spectrum cephalosporins [35].
In the present study, we evaluated the activity of CXA-101
and comparators in a collection of 100 sequential (early-late)
P. aeruginosa isolates, including mucoid and SCV variants,
from 50 chronically-infected CF patients in Spain. The suscep-
tibility proﬁles observed in this CF collection included, in
agreement with data from previous studies [29], an important
number of strains resistant to most currently available anti-
pseudomonal agents, particularly among the late CF isolates.
The overall activity of CXA-101 against CF isolates (in terms
of MICs) was comparable to that of MER, and signiﬁcantly
higher than that of IMP, CAZ, FEP, PTZ, LEV and TOB.
CXA-101 showed conserved activity against a high propor-
tion of isolates resistant to each of the antibiotics tested,
with MIC50 values of 1–2 mg/L and, remarkably, retained
good activity against MDR strains, with MIC50 and MIC90 val-
ues of of 2 and 16 mg/L and MICs £ 8 mg/L for 84% of the
isolates. The activity of CXA-101 was also very high against
late CF isolates, being the only antibiotic tested to which a
similar percentage of early and late isolates was susceptible.
Moreover, CXA-101 was highly potent against mucoid and
SCV phenotypes (mean MIC = 1 mg/L).
These results show that, despite a certain increase in
MICs, major cross-resistance to CXA-101 did not develop
during treatment of CF patients with the currently available
antipseudomonal agents. Therefore, CXA-101 is envisaged as
a potentially valuable antibiotic for the treatment of CRI
caused by P. aeruginosa in CF patients. Thus, the usefulness
of this antibiotic for the treatment of chronic P. aeruginosa
infections in CF patients (in terms of efﬁcacy and reduced
resistance development) should be evaluated in pertinent
clinical trials.
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